10 Cheap Biotech Stocks to Invest in Now

3. Galapagos NV (NASDAQ:GLPG)

P/E Ratio: 6.52 

Galapagos NV (NASDAQ:GLPG) is a Belgian biotech company focused on developing innovative medicines, primarily targeting oncology and immunology. The company specializes in small molecules and cell therapies, including a decentralized CAR-T manufacturing platform that enables fast, personalized treatments. Its pipeline includes promising CAR-T candidates like GLPG5101 and GLPG5201, which are targeting lymphoma and leukemia. Galapagos NV (NASDAQ:GLPG) aims to address unmet medical needs with a focus on conditions like rheumatoid arthritis, Crohn’s disease, and cancer, using cutting-edge science and collaborative approaches.

In Q3 2024, Galapagos NV (NASDAQ:GLPG) reported net revenues of €37.4 million, an 86% decrease from €269.1 million in Q3 2023 due to the divestment of its Jyseleca business. However, the company achieved an operating profit of €66.0 million, up from €23.0 million, driven by lower expenses and increased other operating income. For the first nine months of 2024, total net revenues increased by 11% to €200.1 million, while R&D expenses rose by 42%. The corporation reported a net profit of €48.8 million and a €125.6 million operating loss. The company has €3.3 billion in cash and investments and is expanding its manufacturing capabilities with a new decentralized unit in San Diego to support its clinical trials.

Wall Street analysts set a 12-month price target for Galapagos NV (NASDAQ:GLPG) at an average of $29.75, with a high of $32.00 and a low of $26.00, representing a 24.06% increase from the current price of $23.98.